Berenberg Bank Has Lowered Expectations for Hikma Pharmaceuticals (LON:HIK) Stock Price

Hikma Pharmaceuticals (LON:HIK) had its price objective lowered by stock analysts at Berenberg Bank from GBX 2,100 to GBX 2,050 in a research note issued to investors on Monday, Digital Look reports. The brokerage currently has a “buy” rating on the stock. Berenberg Bank‘s price target suggests a potential upside of 23.05% from the company’s previous close.

HIK has been the topic of several other research reports. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,025 target price on shares of Hikma Pharmaceuticals in a research note on Thursday. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Hikma Pharmaceuticals from GBX 2,050 to GBX 2,000 and set a “buy” rating for the company in a research report on Friday. Finally, Citigroup increased their price target on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Four research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of GBX 1,986.25.

Hikma Pharmaceuticals Trading Up 1.0%

Shares of LON HIK opened at GBX 1,666 on Monday. The company has a debt-to-equity ratio of 77.57, a current ratio of 1.98 and a quick ratio of 1.27. The stock has a market capitalization of £3.45 billion, a P/E ratio of 9.47, a price-to-earnings-growth ratio of 2.38 and a beta of 0.65. Hikma Pharmaceuticals has a 1-year low of GBX 1,187 and a 1-year high of GBX 1,762. The business has a fifty day moving average price of GBX 1,627.89 and a 200 day moving average price of GBX 1,508.93.

Key Hikma Pharmaceuticals News

Here are the key news stories impacting Hikma Pharmaceuticals this week:

• Positive Sentiment: Hikma raised its growth outlook for branded medicines, a positive offset to weakness elsewhere in the business. Hikma Raises Branded Growth Outlook, Narrows 2026 Profit Guidance
• Neutral Sentiment: The company maintained its 2026 revenue guidance and narrowed its operating profit forecast to $740–$760 million. The tighter range gives investors more clarity, but the outlook remains a key focus. Hikma Pharmaceuticals Maintains 2026 Revenue Guidance and Narrows Operating Profit Forecast
• Neutral Sentiment: Jefferies reaffirmed its Buy rating with a GBX 2,025 target, while Deutsche Bank cut its target from GBX 2,050 to GBX 2,000 but retained a Buy rating. Deutsche Bank rating information
• Negative Sentiment: Hikma lowered its outlook for Injectables. That business outlook revision is the clearest near-term headwind and likely weighs on sentiment despite the brighter branded-medicines forecast. Hikma Pharmaceuticals shares down as cuts Injectables outlook

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.